**GEMINI**:
This is an incredibly impressive evolution. Going from a single-fold proxy-ROI medical study (V1) to a dual-domain, 5-fold cross-validated, rigorous benchmarking paper (V3) is exactly the kind of maturity required for top-tier venues. You have systematically eliminated the "fatal flaws" that typically get papers desk-rejected at venues like BMVC or Medical Image Analysis (MedIA - Q1 Journal).

Here is a thorough, reviewer-style assessment of your V3 project, including strengths, weaknesses, ratings, and a prioritized action plan.

---

### 1. Strengths (What Reviewers Will Love)
*   **The Cross-Domain Proof:** This is the "killer feature" of your paper. Showing that the exact same architecture hierarchy (DenseNet agreeing most, ViT agreeing least) happens on both clinical MRI and CUB-200 elevates this from a niche medical paper to a fundamental Computer Vision finding. BMVC reviewers will respect this.
*   **Exceptional Statistical Rigor:** 5-fold CV with bootstrap confidence intervals over 147,000+ attribution maps is massive. Most XAI papers use 1-3 datasets but only do single-pass evaluations. You have mathematically proven that the disagreement isn't noise.
*   **Preemptive Strike on Reviewer Critiques:** You included the Adebayo Randomization Sanity Check. Reviewers *always* ask for this. Having it already in the paper blocks a major avenue for rejection.
*   **The Narrative Arc is Complete:** You don't just point out a problem (disagreement); you offer a post-hoc solution (Faithfulness-Weighted Consensus) and an ante-hoc alternative (Concept Bottleneck Models with intervention). 
*   **Expert Clinical Annotations:** For the MIDL/Medical journal side, using actual RSNA neuroradiologist coordinates instead of proxy bounding boxes provides immense credibility.

### 2. Weaknesses (Vulnerabilities to Address)
*   **The ConvNeXt-CUB Training Failure (Critical):** Reporting a 32% accuracy for ConvNeXt-Tiny on CUB-200 is a glaring red flag for a computer vision conference. Reviewers will think: *"If they couldn't tune the hyperparameters to get a standard backbone to converge on a standard dataset, how can I trust the rest of their pipeline?"* 
*   **"Architecture Family" Claims Based on One Model:** You claim that the disagreement mechanism in Transformers is fundamentally different from CNNs. However, you only tested *one* Transformer (ViT-Small). A reviewer might argue this is a "ViT" quirk, not a "Transformer" property.
*   **Feature Map Smoothness is a "Dead End" in the Narrative:** While negative results are scientifically valid, ending a section by saying "Feature coherence doesn't predict agreement in Transformers" leaves the reader hanging. It begs the question: *So what DOES cause it?* 

---

### 3. Reviewer Rating & Evaluation (Top-Tier Venue Perspective)

If I were an Area Chair (AC) for BMVC or a reviewer for a Q1 Journal (e.g., IEEE TMI or MedIA), here is how I would score your current V3 state:

*   **Originality & Novelty: 8/10 (Strong)**
    *   *Justification:* The disagreement problem is known (Krishna et al.), but proving it is *architecture-dependent* across domains is novel. The Faithfulness-Weighted Consensus Map is a clever, practical contribution.
*   **Technical Quality & Rigor: 8.5/10 (Very Strong, borderline Excellent)**
    *   *Justification:* 5-fold CV, 7 XAI methods, Adebayo checks, and expert ROIs are fantastic. It loses 1.5 points solely due to the ConvNeXt training failure and missing ViT fold 0 rollout.
*   **Significance & Impact: 9/10 (Excellent)**
    *   *Justification:* The medical XAI community is desperate for guidelines. Proving that classic CNNs are safer for XAI than modern architectures, and proving ante-hoc CBMs actually work, is highly impactful.
*   **Clarity & Presentation: 9.5/10 (Exceptional)**
    *   *Justification:* Based on the narrative arc outlined in your report, the storyline is incredibly cohesive.

**Overall Verdict: YES, it is top-tier worthy.** 
However, if submitted *exactly* as it is today, the ConvNeXt failure and single-transformer limitation might result in a "Borderline Accept" or "Major Revision." A few small additions will push it to a definitive "Strong Accept."

---

### 4. Next Steps & Code Execution Priority

You should **start drafting the manuscript right now**, as writing takes time. However, you need to run a few background tasks simultaneously. Here is the triage:

#### 🔴 Tier 1: MUST HAVES (Do this before submission)
*   **Fix ConvNeXt on CUB-200 (Estimated GPU: 4-6 hours):** You *cannot* publish a 32% accuracy baseline in a CV venue. Drop the learning rate, change the optimizer to AdamW with weight decay, or use `timm`'s built-in fine-tuning script. Get it to >75% accuracy and re-run its XAI benchmark.
*   **Re-run ViT Fold 0 Attention Rollout (Estimated GPU: 30 mins):** Fix the missing data. Do not submit a paper with an asterisk saying "we skipped fold 0 due to a bug."

#### 🟡 Tier 2: MASSIVE ROI / HIGHLY RECOMMENDED (Guarantees higher acceptance chance)
*   **Add ONE more Transformer (e.g., Swin-Tiny or DeiT-Small) (Estimated GPU: 10-15 hours):** 
    *   *Why?* You make a massive claim that Transformers behave fundamentally differently than CNNs regarding XAI agreement. Proving this holds true on a hierarchical transformer (Swin) alongside an isotropic one (ViT) completely bulletproofs your paper against "reviewer 2" complaining about sample size.
    *   *Action:* Train Swin-Tiny on both RSNA and CUB-200, run the XAI benchmark.

#### 🟢 Tier 3: NICE TO HAVES / LOW IMPACT (Skip or mention in limitations)
*   **Fixing the Feature Coherence "Why":** You proved coherence doesn't cause Transformer disagreement. You don't need to invent a new theory; just explicitly state in the paper: *"We hypothesize the disagreement stems from the non-local routing of self-attention gradients, which we leave for future work."*
*   **BiomedCLIP Features:** You correctly diagnosed this as noisy. Skip entirely. Do not even mention it in the paper unless a reviewer explicitly asks about text-based concepts during the rebuttal phase.
*   **LIME / SHAP / Captum additions:** Your 7 methods are plenty. Skip.

### Strategic Advice on Writing the Draft

Since you are aiming for BMVC (Computer Vision) or a Q1 Journal:

1.  **If targeting BMVC:** Title it something like *"Architecture Governs Explanation..."* Lead heavily with the CUB-200 and cross-domain findings. The clinical spine MRI should be framed as the "real-world safety-critical application."
2.  **If targeting a Q1 Medical Journal (MedIA, IEEE TMI) or MIDL:** Title it something like *"The Disagreement Problem in Clinical XAI..."* Lead with the Spine MRI, the clinical danger of disagreement, and the expert annotations. Frame CUB-200 as the "proof of theoretical generalization."
3.  **Regarding the CBM:** Make sure you emphasize that your programmatic, non-leaky concepts (like `adjacent_pathology_density`) provide a 59.2% intervention fix rate. This proves that interpretable models *can* be mathematically competitive with black boxes while being vastly safer.

**Final Recommendation:** Start writing the methodology and literature review sections today. In the background, launch the hyperparameter fix for ConvNeXt on CUB-200, and (if you have the compute budget) add Swin-Transformer. Once those are done, generate your final plots, and you will have a rock-solid, top-tier manuscript.



**sonnet**:
Now I have enough to write a thorough, honest review. Let me build this properly.Here is the full, honest review — written the way a senior BMVC/MIDL program committee member would think about it.

---

## Overall verdict

This is a solid empirical study with good statistical rigor that lands as a borderline accept at BMVC and a likely accept at MIDL. Its biggest risks are not experimental — the data is strong. The risks are positional: two papers published in the last 18 months land very close to your core claim, and one of them (LATEC) is strictly larger in scope. If you walk into a review without explicitly neutralizing those two, you will get rejected on novelty alone regardless of your results.

---

## Strengths — where this paper is genuinely strong

**Cross-domain design is the paper's single best asset.** Reproducing the same architecture-dependent disagreement hierarchy on both clinical spine MRI and CUB-200 fine-grained classification is a legitimately novel design choice that no prior XAI benchmark paper has done in exactly this way. The key insight — that DenseNet ranks #1 and ViT ranks last in agreement on both datasets — is striking and publishable on its own.

**Statistical rigor exceeds most benchmark papers.** Five-fold CV with bootstrap confidence intervals, patient-level stratification, and reported mean ± std on every single metric is genuinely better than the majority of what gets published at BMVC. Most papers in this space report single-fold results. This will be noticed positively.

**Expert annotations, not proxy ROIs.** This was the right call and reviewers in clinical AI will notice it. The V1 → V2 fix here was critical.

**Faithfulness-Weighted Consensus Map is novel.** Using per-method insertion AUC as weights to produce a consensus attribution is something nobody has published as a standalone contribution. It works (matches or beats best individual method on all architectures) and it provides a practical resolution to a real practitioner problem.

**CBM intervention result tells a complete story.** The 59.2% error correction rate from the non-leaky CBM, combined with demonstrating the inflated 84.6% from the leaky ablation, gives reviewers a clean before/after that validates your methodology and adds clinical utility beyond the benchmark.

**The four-act narrative structure is strong.** Problem → Architecture-dependent → Resolve with consensus → Better path with ante-hoc. This is a complete, satisfying arc that most benchmark papers lack.

---

## Weaknesses — where reviewers will push back hard

**The LATEC problem is existential for your novelty claim.** LATEC, published at NeurIPS 2024 Datasets and Benchmarks Track, evaluates 17 XAI methods across 20 distinct metrics, systematically incorporating varied architectures and diverse input modalities, resulting in 7,560 examined combinations. Your paper currently claims to be "the largest XAI disagreement benchmark to date." That claim is demonstrably false, and a BMVC reviewer who knows the field will catch it in the first read. You don't need to be larger than LATEC — you need to be *different* from it in a way that is clearly articulated. LATEC focuses on metric reliability and ranking stability; you focus on cross-domain pattern reproduction, clinical deployment, and resolution methods. That differentiation is real, but you have to make it explicit in the paper.

**"Hypothesis Class Determines Explanation" (arXiv, March 2026) overlaps your core thesis almost exactly.** That paper conducts a large-scale empirical study across 24 datasets and multiple model classes, finding that models with identical predictive behavior can produce substantially different feature attributions, with disagreement being highly structured — models within the same hypothesis class exhibit strong agreement, while cross-class pairs show substantially reduced agreement. The paper identifies hypothesis class as the structural driver of this phenomenon. This is essentially the same claim you're making, framed slightly differently (they fix the XAI method and vary the model; you fix the model and vary the XAI method). It's a preprint, not yet published at a venue, so you can still race it — but you cannot ignore it. You need to cite it and articulate the orthogonal contribution clearly.

**ConvNeXt on CUB-200 at 32% accuracy is a methodological problem, not just a limitation.** XAI attribution maps from a model performing near-random on a 200-class problem have no interpretive value. The fact that it's included in any CUB XAI table, even with a footnote, invites the question: why is it there at all? The correct fix is hard exclusion with a brief methods note. Don't "retrain with tuned hyperparameters" — that would take more time and still produces a model trained on a different protocol than your other four. Just cut it.

**No public code or data release.** For a benchmark paper submitted in 2027, this is now expected as a baseline condition of submission, not a nice-to-have. LATEC released 326k saliency maps and 378k metric scores publicly. A reviewer comparing your two papers will notice immediately that LATEC is fully reproducible and yours is not. You don't need to release the RSNA images (they're competition data with restrictions), but you need to release at minimum: your trained model weights, your XAI attribution maps (as numpy arrays or similar), your evaluation scripts, and your CUB-200 pipeline. A GitHub repository before submission is now effectively required to compete in the benchmark paper category.

**Feature Coherence analysis with p=0.414 is not a finding, it's a null result.** Pearson r=0.48 at N=5 data points is statistically meaningless and the p-value confirms it. You can report this as an informative negative — "feature coherence does not predict XAI agreement" — but you cannot present it as revealing "that the ViT disagreement mechanism is categorically different from CNNs" without N=1 ViT being a confound. The CNN-only sub-correlation (DenseNet > ResNet > ConvNeXt matching the agreement ordering) is more interesting but still very small N. Keep this in supplementary; don't give it a results section heading.

**Only one Transformer is a serious weakness for the "Transformers disagree more" claim.** ViT-Small is a single data point. A reviewer will correctly say: "What about Swin Transformer? DeiT? They have different attention mechanisms and different gradient flow properties. The claim may not generalize to Transformers broadly." This is your weakest methodological gap and the one most likely to generate a rejection recommendation on its own.

---

## Priority-tiered action plan — what to do before writing the draft

### Tier 1: Must-haves before submission (these are blocking)

**1. Write a "Relation to LATEC and Contemporary Work" paragraph (zero GPU, 2–3 hours writing).** This is the single highest ROI action available to you. Explicitly compare to LATEC: LATEC studies metric reliability across modalities; your paper studies cross-domain pattern reproduction in clinical and natural images with a concrete resolution method. These are orthogonal contributions. Then handle the "Hypothesis Class" paper: they vary the model and fix the XAI method; you fix the model and vary the XAI method. The intersection is the finding that architecture governs disagreement; the differentiation is your cross-domain proof and clinical deployment context.

**2. Hard-exclude ConvNeXt from all CUB-200 XAI analysis and tables (no GPU needed, 1 hour).** Remove it from Table 9.4. Update any cross-domain consistency claims to be based on the four competent models only. Add one sentence in the methods: "ConvNeXt-Tiny failed to converge on CUB-200 under our training protocol (32% top-1 accuracy). Since XAI analysis of incompetent classifiers produces uninterpretable attributions, we exclude it from all CUB-200 XAI evaluation." This is honest, explains the gap, and pre-empts the reviewer concern.

**3. Release code publicly on GitHub before submitting (zero GPU, 4–8 hours of cleanup).** At minimum: CUB-200 training and XAI scripts, RSNA XAI scripts (not the raw data, which has competition restrictions), all aggregation and figure generation scripts, and ideally the trained model weights on HuggingFace or Zenodo. Add a `README.md` with exact reproduction commands. This alone can flip a borderline rejection to a borderline accept.

**4. Re-run ViT fold 0 Attention Rollout (30 minutes GPU).** You noted this yourself. Do it first — it's trivial and closes a gap in your own tables.

### Tier 2: High-value additions that do require code (do these if you have 1–2 weeks)

**5. Add one more Transformer architecture — DeiT-Small or Swin-Tiny (4–6 GPU hours).** If DeiT and ViT both show low agreement while CNNs show high agreement, your "architecture class governs explanation" claim becomes N=2 Transformers vs. 4 CNNs, which is defensible. DeiT is nearly the same size as ViT-Small and uses the same timm training interface — it would slot directly into your existing CUB-200 pipeline with minimal code changes. This is the single code addition most likely to push you from borderline to accept.

**6. Move Feature Coherence to supplementary and rewrite it honestly.** In the main paper, give it two sentences: "We investigated whether spatial feature map coherence predicts XAI agreement (see Supplementary §X). Within the CNN family, coherence ordering matches agreement ordering; across the full architecture set including ViT, the correlation does not hold (r=0.48, p=0.41), indicating that the Transformer disagreement mechanism operates through gradient flow rather than feature fragmentation." This is an honest framing of a null result that adds mechanistic depth without overclaiming.

### Tier 3: Nice-to-haves that would not move the needle enough to justify the effort

Adding LIME or KernelSHAP — your justification for exclusion is solid. BiomedCLIP concepts — you investigated it and it failed. A third dataset — diminishing returns given the CUB-200 generalization already established. Adding uncertainty quantification to attributions — this is a separate research direction and reviewers will not expect it.

---

## Should you start writing the draft now?

Not yet — do Tier 1 first (items 1–4), which requires no GPU at all. Items 1–3 are pure writing and repository work that will take 1–2 days. Item 4 is 30 minutes. After those four actions, yes, start writing, because the paper's core story is complete and strong.

If you then have another week before your submission deadline, do item 5 (add DeiT). It's the one code addition that meaningfully changes your reviewer's perception of the architecture-dependence claim from "interesting observation with limited evidence" to "demonstrated pattern."

---

## Venue recommendation

**Primary target: MIDL 2027.** The clinical alignment results, expert annotation evaluation, CBM intervention study, and the spine MRI domain make this a natural fit for MIDL's audience. MIDL reviewers will care more about the clinical utility demonstration and less about whether you have 7 XAI methods or 17. Your paper is one of very few XAI disagreement studies that uses real expert annotations and demonstrates a practical clinical resolution (CBM intervention with 59.2% fix rate). That is a genuinely strong submission to MIDL.

**Secondary target: BMVC 2027.** BMVC 2025 accepted 31.9% of submissions (276 out of 865). Your paper at its current state would likely be rejected on the LATEC novelty concern. After the Tier 1 writing fixes and ideally the DeiT addition, it becomes a reasonable borderline-accept submission for BMVC — particularly if you lead with the CUB-200 cross-domain story and position the clinical data as the validation domain.

**Do not target CVPR/ECCV/NeurIPS** at this stage. The gap between your 7-method study and LATEC's 17-method, 20-metric, 7,560-combination study is too large to overcome without a fundamentally expanded scope, and LATEC's existence at NeurIPS makes that venue particularly hostile to your current framing.

If you want a Q1 journal path alongside the conference submission, **Medical Image Analysis (MedIA)** or **IEEE Transactions on Medical Imaging (TMI)** would be natural homes — the journal format gives you space to handle the Transformer limitation properly and to add the DeiT experiment with full analysis. Both are Q1 and both publish XAI benchmark work in medical imaging.


**sam alt**:
I went through the full V3 report carefully. 

This is not a “student-project-level benchmark” anymore. It has crossed into the territory of a legitimate research submission with a real thesis, meaningful experimental scale, and a publishable narrative structure.

But it is also not yet at the “high-confidence BMVC accept” level.

Right now, I would classify it as:

| Venue Tier                        | Current Probability      |
| --------------------------------- | ------------------------ |
| Mid-tier workshop                 | Very high                |
| Solid Q2 journal                  | High                     |
| MIDL main conference              | Moderate-to-good         |
| BMVC main conference              | Borderline but plausible |
| CVPR/ICCV/ECCV main               | Low in current state     |
| Strong Q1 journal after polishing | Realistic                |

The important thing is *why*.

---

# Overall Reviewer Impression

If I were a BMVC/MIDL reviewer, my immediate reaction would be:

> “This is surprisingly mature work for an independently executed benchmark project. The experimental scale is strong, the narrative is coherent, and the cross-domain reproduction is the paper’s main strength. However, the theoretical depth and novelty ceiling are still somewhat limited, and there are a few reviewer attack surfaces that could hurt acceptance.”

That is a *good* place to be.

Most rejected papers fail because:

* experiments are weak,
* claims are unsupported,
* novelty is superficial,
* evaluation is sloppy,
* or the paper lacks a clean narrative.

Your project avoids most of those fatal issues.

---

# The Single Biggest Strength

The strongest part of the paper is NOT the medical imaging angle.

It is THIS:

> Architecture-dependent XAI disagreement reproduces across two fundamentally different domains.

That is the line that upgrades this from:

* “another medical XAI paper”

to:

* “a computer vision benchmark contribution.”

This is absolutely the correct strategic move for BMVC. 

Without CUB-200:

* reviewers would likely push this toward MICCAI/MIDL only.

With CUB-200:

* you now have a defensible cross-domain architecture claim.

That was the right decision.

---

# Parameter-by-Parameter Reviewer Evaluation

# 1. Problem Importance

### Rating: 8.5/10

This is a real problem:

* explainability inconsistency,
* trust calibration,
* medical deployment reliability,
* architecture-specific XAI behavior.

You correctly tied it to:

* clinical trust,
* safety,
* and explanation reliability. 

That gives the paper practical relevance.

### Reviewer View

A reviewer would likely say:

> “The problem itself is important and timely.”

This helps significantly.

---

# 2. Novelty

### Rating: 7.2/10

This is where the paper is strongest *and* weakest simultaneously.

## What is genuinely novel

### Strong novelty

* Cross-domain architecture-dependent disagreement benchmark
* Faithfulness-weighted consensus framework
* Combined medical + natural image validation
* Architecture-family interpretation of disagreement
* CBM framing as a disagreement alternative

### Moderate novelty

* Benchmark scale
* Feature coherence analysis
* Attention Rollout comparison

### Weak novelty

* Core disagreement idea itself is NOT new
* XAI benchmarking is a crowded area
* Most methods are existing methods

So the paper’s novelty comes from:

* synthesis,
* scale,
* breadth,
* and framing.

Not from a revolutionary algorithm.

That is acceptable for BMVC if execution quality is strong enough.

---

# 3. Experimental Rigor

### Rating: 9/10

This is honestly one of the strongest parts.

You fixed almost every major benchmark-paper weakness:

* 5-fold CV
* bootstrap confidence intervals
* multiple datasets
* expert annotations
* randomization sanity checks
* multiple architecture families
* multiple XAI families
* intervention experiments
* faithfulness metrics

This is *substantially above average* for student-led work.

The paper feels “serious” experimentally.

That matters enormously.

---

# 4. Statistical Credibility

### Rating: 8.3/10

Good:

* fold averaging,
* std reporting,
* ranking consistency,
* confidence intervals,
* stable trends.

Weakness:

* lack of formal significance testing.

This is one of the few things that can materially improve acceptance odds.

You should add:

* paired statistical tests,
* confidence intervals on rank differences,
* effect size reporting.

For example:

* DenseNet vs ViT agreement difference significance,
* CNN-family vs Transformer-family significance,
* consensus vs best-single-method significance.

This is currently missing.

A strong reviewer may ask:

> “Are these differences statistically significant or just descriptive?”

---

# 5. Narrative Quality

### Rating: 9/10

The narrative structure is surprisingly good. 

The four-act structure is publication-quality thinking.

Especially strong:

1. Problem exists
2. Cross-domain reproduction
3. Resolution exists
4. Ante-hoc alternative

That is very good paper architecture.

Most student papers lack this completely.

---

# 6. Technical Depth

### Rating: 6.8/10

This is probably the biggest weakness for top-tier acceptance.

Right now, the paper is:

* experimentally strong,
* empirically convincing,
* but theoretically light.

A BMVC reviewer may say:

> “Good benchmark, but limited mechanistic insight.”

Especially because:

* Feature Coherence ended up inconclusive. 

This matters.

You need at least ONE deeper mechanistic angle.

---

# 7. Reproducibility

### Rating: 9.2/10

Excellent.

The codebase structure is unusually clean for this scale. 

This helps reviewers psychologically:

* the project feels organized,
* real,
* reproducible,
* credible.

Huge advantage.

---

# 8. Clinical Relevance

### Rating: 8/10

Strong enough for MIDL/MICCAI-adjacent venues.

The use of:

* real neuroradiologist coordinates,
* intervention analysis,
* clinical anatomy,
* concept bottlenecks

adds legitimacy.

Good move abandoning noisy BiomedCLIP concepts. That was correct scientifically. 

---

# 9. Benchmark Design

### Rating: 8.8/10

This is another major strength.

The benchmark matrix is genuinely substantial:

* 7 architectures
* 7 XAI methods
* 2 datasets
* 5-fold CV
* 147k+ maps

That scale creates reviewer confidence.

---

# 10. Publication Readiness

### Rating: 6.5/10

Experimentally:

* yes.

Manuscript-wise:

* not yet.

You are still missing several things that strongly affect acceptance probability.

---

# What Would Likely Happen at BMVC Right Now?

## Likely Reviewer Distribution

### Reviewer A

Positive:

> “Strong benchmark, broad evaluation, meaningful empirical finding.”

### Reviewer B

Mixed:

> “Interesting but incremental. Mechanistic insight limited.”

### Reviewer C

Mixed-negative:

> “Primarily an empirical benchmark paper with limited methodological novelty.”

That combination often becomes:

* borderline reject,
* weak reject,
* or weak accept depending on writing quality.

---

# Current Estimated Acceptance Odds

| Venue                             | Estimated State  |
| --------------------------------- | ---------------- |
| BMVC                              | Borderline       |
| MIDL                              | Competitive      |
| Medical Imaging Journal Q1        | Good chance      |
| IEEE TMI                          | Probably not yet |
| Medical Image Analysis            | Not yet          |
| Pattern Recognition               | Realistic        |
| Computers in Biology and Medicine | Very realistic   |

---

# The MOST Important Question:

# Should You Start Writing Now?

## YES — but only AFTER completing a short list of high-impact additions.

You are very close to the point where extra experimentation gives diminishing returns.

Do NOT spend another 3 months running random experiments.

That would be a mistake.

Instead:

* do a few strategic additions,
* then shift hard into writing quality.

At this stage, writing quality matters enormously.

---

# The Highest-Impact Remaining Additions

# MUST-HAVE (Strongly Recommended Before Submission)

## 1. Statistical Significance Testing

### Priority: MUST-HAVE

This is the single highest ROI addition now.

Add:

* paired t-tests,
* Wilcoxon signed-rank,
* effect sizes,
* corrected p-values.

Especially for:

* DenseNet vs ViT,
* CNN vs Transformer,
* Consensus vs Best Single Method.

This massively improves reviewer confidence.

### Acceptance impact:

HIGH

---

# 2. Qualitative Disagreement Gallery

### Priority: MUST-HAVE

You mention it, but the paper absolutely needs:

* side-by-side saliency visualizations,
* “same image, different explanations,”
* best/worst cases,
* transformer pathology examples.

Without this:

* the paper becomes overly numeric.

A strong qualitative figure can materially improve acceptance odds.

### Acceptance impact:

VERY HIGH

---

# 3. Stronger Failure Analysis

### Priority: MUST-HAVE

Right now:

* you report findings,
* but you don't deeply analyze failures.

You need:

* WHY ViT fails,
* WHY DenseNet agrees,
* WHY EfficientNet flips,
* WHY ConvNeXt destabilizes.

Even speculative but well-reasoned analysis helps.

This is crucial for top-tier reviewers.

---

# 4. Ablation on Consensus Weighting

### Priority: MUST-HAVE

Right now reviewers can ask:

> “Why faithfulness weighting specifically?”

You need comparison against:

* equal weighting,
* best-single-method,
* random weighting,
* entropy weighting.

This is extremely important.

Without it:

* consensus may feel under-validated.

---

# HIGH-VALUE NICE-TO-HAVES

# 5. Add One More Transformer

### Priority: NICE-TO-HAVE

This would significantly strengthen the architecture claim.

Even one of:

* DeiT,
* Swin,
* Tiny ViT.

would help a lot.

Right now:

* “Transformer claim” rests mostly on one model.

That is a legitimate reviewer weakness.

### Acceptance impact:

Moderate-to-high

---

# 6. Human Preference Study

### Priority: NICE-TO-HAVE

Even a small:

* clinician,
* graduate student,
* or blind ranking study

comparing:

* consensus maps,
* individual methods

would massively strengthen the practical argument.

This is surprisingly powerful for reviewers.

---

# 7. Robustness Under Augmentation

### Priority: NICE-TO-HAVE

Check explanation consistency under:

* small rotation,
* contrast shift,
* Gaussian noise.

This adds another strong axis.

---

# LOW PRIORITY

# 8. More Datasets

### Priority: LOW

Do NOT dataset-spam.

Two datasets are enough.

Three is okay.

Four becomes unnecessary unless very strategic.

---

# 9. More XAI Methods

### Priority: LOW

You already have enough diversity.

Adding more may dilute clarity.

---

# The Single Most Important Strategic Insight

Right now your paper’s acceptance will depend less on:

* raw experimental scale

and more on:

* interpretation quality,
* clarity,
* reviewer trust,
* and narrative sharpness.

This is where many technically good projects fail.

---

# What Would MASSIVELY Increase Acceptance Odds?

These are the biggest possible improvements now:

| Addition                       | Impact        |
| ------------------------------ | ------------- |
| Strong qualitative figures     | Massive       |
| Statistical significance tests | Massive       |
| One extra transformer          | High          |
| Consensus ablation             | High          |
| Better mechanistic discussion  | High          |
| Excellent writing/presentation | Massive       |
| Human evaluation               | Moderate-high |
| Better theorem/theory          | Moderate      |

---

# Theoretical Weakness — The Hard Truth

If you want true top-tier CVPR/ICCV-level competitiveness:
you would eventually need either:

* stronger theory,
* or a fundamentally new XAI framework.

Right now:

* the work is closer to a very strong empirical benchmark paper.

That is still absolutely respectable research.

But it's important to understand where the ceiling currently is.

---

# Final Verdict

# Is this worthy of a top-tier venue?

## Current State:

### Borderline for BMVC main conference

### Competitive for MIDL

### Strong for good Q1/Q2 journals

---

# My Overall Scores

| Category               | Score |
| ---------------------- | ----- |
| Problem Importance     | 8.5   |
| Novelty                | 7.2   |
| Experimental Rigor     | 9.0   |
| Statistical Quality    | 8.3   |
| Narrative              | 9.0   |
| Technical Depth        | 6.8   |
| Reproducibility        | 9.2   |
| Clinical Relevance     | 8.0   |
| Benchmark Design       | 8.8   |
| Overall BMVC Readiness | 7.8   |

---

# Final Recommendation

Do NOT immediately submit.

Do this first:

## MUST DO BEFORE WRITING FINAL DRAFT

1. Statistical significance tests
2. Consensus weighting ablation
3. Strong qualitative disagreement gallery
4. Deeper failure analysis discussion
5. Re-run missing ViT Attention Rollout fold

## STRONGLY RECOMMENDED

6. Add one more transformer if feasible

Then:

* freeze experiments,
* stop adding features,
* focus entirely on paper quality.

Because at your current stage:

* writing quality,
* figures,
* framing,
* and reviewer psychology

will matter more than another 20 GPU hours.

And importantly:

This project is already beyond the level where you should think:

> “Is this real research?”

Yes — this is real research work now.


**glm**:

# SpineXNet V3: Full Peer Review Assessment

---

## 1. STRENGTHS

### S1. Cross-Domain Generalization is a Genuine Contribution
The finding that the XAI disagreement hierarchy (DenseNet > ResNet >> ConvNeXt > EfficientNet > ViT) reproduces on both clinical spine MRI *and* CUB-200 fine-grained bird classification is, to my knowledge, unprecedented. No prior XAI disagreement study has demonstrated architecture-dependent disagreement that transcends imaging domains. This single finding elevates the paper from "medical imaging case study" to "fundamental computer vision observation." It is the paper's strongest asset and should be front-and-center in every version of the abstract.

### S2. Scale and Rigor of the Benchmark
147,000+ attribution maps, 7 architectures × 7 XAI methods × 5-fold CV × 2 datasets, with bootstrap confidence intervals — this is an unusually thorough benchmark. Most XAI papers test 2–3 methods on 1–2 models with a single train/test split. The fact that every metric has mean ± std across 5 folds, and that the hierarchy is *stable* across all folds, is compelling. A reviewer cannot dismiss this as underpowered.

### S3. Expert Annotations, Not Proxy ROIs
Using real neuroradiologist coordinate annotations from RSNA for clinical alignment evaluation is a meaningful differentiator. Many medical XAI papers fabricate ground truth via bounding boxes or programmatic masks. Having expert coordinates makes the clinical alignment axis defensible and reviewers will notice this.

### S4. Honest Treatment of Negative Results
The Feature Coherence analysis producing a null result (ViT has the *highest* coherence yet the *lowest* agreement) is handled transparently. This is actually a more interesting finding than if it had confirmed the hypothesis — it reveals that Transformer disagreement is mechanistically different from CNN disagreement. Framed correctly, this becomes a strength, not a weakness.

### S5. Randomization Sanity Checks
Preemptively including Adebayo et al. sanity checks removes a standard reviewer attack vector. This signals methodological maturity.

### S6. The Narrative Arc is Well-Structured
The four-act story (problem is real → it's architectural → here's a resolution → here's a better path) is clean and compelling. The paper has a natural escalation of stakes that keeps a reader engaged.

### S7. CBM as Ante-Hoc Alternative Completes the Story
Many benchmark papers identify problems without proposing solutions. Including the CBM with concept intervention (59.2% error correction) gives the paper a constructive ending rather than just a diagnostic one.

---

## 2. WEAKNESSES

### W1. Single Transformer Architecture — Critical Vulnerability
The paper's central claim is "Architecture Governs Explanation." Yet the entire Transformer evidence rests on **one model: ViT-Small**. A reviewer will rightfully ask: "How do you know this is a Transformer property and not a ViT-Small property?" The title claims architectural governance, but the empirical foundation for the most novel part of the hierarchy (Transformers disagree more) is a single data point. This is the paper's most significant structural weakness.

### W2. ConvNeXt CUB-200 Training Failure Undermines Cross-Domain Claims
ConvNeXt-Tiny achieving 32% accuracy on CUB-200 (barely above random for 200 classes is ~0.5%, but far below competent) means you lose one of your seven architectures in the cross-domain comparison. More concerning: a reviewer may question whether your training protocol is fair. If ConvNeXt works on RSNA but fails on CUB-200, perhaps the RSNA results are also fragile. You need either a fix or an extremely transparent acknowledgment.

### W3. Faithfulness-Weighted Consensus Map is Methodologically Thin
The consensus map is a weighted average: `Σ(w_i × map_i) / Σ(w_i)` where weights are Insertion AUC scores. This is a one-line equation. While the *evaluation* showing it works is valuable, the *method* itself is trivially simple. A reviewer at BMVC will ask: "Where is the technical contribution?" The defense must be that the contribution is the benchmark + the finding, not the consensus method — but this needs to be framed carefully.

### W4. CBM Concepts Are Metadata-Derived, Not Learned
`is_stenosis`, `left_laterality`, `level_position` are deterministic functions of the input metadata, not learned visual concepts. A CBM purist (and there are many at MIDL) will argue this is not a true Concept Bottleneck Model — it's a structured prediction model with metadata conditioning. The concept intervention results (59.2%) are less impressive when the "concepts" are just rule-based features. This weakens Act 4 of the narrative.

### W5. Feature Coherence Analysis is Statistically Underpowered
With n=5 architectures, the Pearson r=0.48 (p=0.414) and Spearman ρ=0.00 (p=1.000) are essentially uninformative. You cannot draw conclusions from 5 data points. The claim that "within CNNs, coherence predicts agreement" is based on 4 data points with no formal test. This section will attract statistical scrutiny.

### W6. No Significance Tests Between Methods
You report DenseNet ρ=0.434 ± 0.023 vs ViT ρ=0.200 ± 0.028. These look different, but you never test whether they *are* significantly different. With 5 folds, a paired Wilcoxon signed-rank test or paired t-test would take minutes to compute and would dramatically strengthen every comparison in the paper. Their absence is a gap a reviewer will notice.

### W7. Insertion/Deletion AUC as Faithfulness Ground Truth
Insertion and Deletion AUC are themselves debated metrics. Known issues include: sensitivity to perturbation baseline, confound with model sensitivity to occlusion, and correlation with model confidence rather than explanation quality. A reviewer may challenge whether your consensus map weights are trustworthy if the faithfulness metric itself is questionable.

### W8. EfficientNet Ranking Flip Between Domains
EfficientNet-B4 goes from 6th (RSNA, ρ=0.223) to 3rd (CUB-200, ρ=0.412). While the top-2 and bottom positions are stable, this mid-tier instability suggests the hierarchy is not *perfectly* architecture-determined — domain plays a role. A careful reviewer will note this and ask you to soften the "Architecture Governs Explanation" title/claim.

---

## 3. PARAMETER RATINGS

| Parameter | Rating (1–10) | Justification |
|-----------|:---:|---|
| **Novelty** | 6.5 | Cross-domain architecture-dependent disagreement is new. But individual components (XAI disagreement, consensus, CBM) are not novel individually. Contribution is primarily empirical. |
| **Technical Soundness** | 7.0 | 5-fold CV, bootstrap CIs, sanity checks, expert annotations are strong. But single Transformer, ConvNeXt failure, and underpowered coherence analysis deduct. |
| **Significance / Impact** | 7.0 | The cross-domain finding matters. Clinical relevance is real. But the methodological contribution (weighted average) is thin, limiting impact depth. |
| **Experimental Rigor** | 7.5 | Scale is impressive (147K+ maps). Missing: significance tests, multiple-comparison correction, perturbation baseline analysis. |
| **Clarity / Presentation** | 8.0 | The report is exceptionally well-organized. The four-act narrative is compelling. Honest about limitations. |
| **Reproducibility** | 7.0 | Code structure is clean. Kaggle notebooks exist. But no explicit commitment to release code/data upon publication. |
| **Completeness** | 6.5 | ConvNeXt failure, single Transformer, no LIME, metadata-only concepts. Several gaps remain. |
| **Clinical Relevance** | 8.0 | Expert annotations, concept intervention, real clinical conditions. Strong for MIDL. |
| **Theoretical Depth** | 5.0 | No formal theory. Feature coherence analysis is underpowered. The "why" behind the hierarchy is mostly speculative. |
| **Venue Fit (BMVC)** | 7.0 | CUB-200 helps enormously. Still medical-imaging-heavy. A CV reviewer may still say "go to MICCAI." |
| **Venue Fit (MIDL)** | 8.5 | Clinical spine analysis + CBM + expert alignment = strong MIDL fit. Cross-domain generalization is a bonus. |

**Composite Score: 7.0 / 10**

---

## 4. ACCEPTANCE VERDICT

### For BMVC 2027: **Borderline (lean Accept with improvements, Reject as-is)**

As the project stands right now, I estimate a **40–50% acceptance probability** at BMVC. The cross-domain finding is genuine and the benchmark is thorough, but the single Transformer, ConvNeXt failure, and thin methodological novelty give a reviewer enough ammunition to reject. BMVC reviewers in the XAI/interpretability track will be demanding — they see many "XAI methods disagree" papers.

**With targeted improvements (see §5), I estimate this rises to 65–75% acceptance probability.**

### For MIDL 2027: **Likely Accept (70–80%)**

MIDL values clinical relevance more than methodological novelty. The expert annotations, concept intervention, and clinical alignment evaluation are strong selling points. The CUB-200 generalization is a bonus, not a requirement. The single Transformer is less of a concern here.

### For Q1 Journal (e.g., Medical Image Analysis, IEEE TMI): **Not Ready (30–40%)**

Top Q1 journals want more depth: multiple transformers, learned concepts (not metadata), theoretical grounding, and a third dataset. The current work is a strong conference paper but needs 2–3 more months of work for journal readiness.

---

## 5. ACTION ITEMS: WHAT TO DO BEFORE WRITING

### Priority Classification System
- 🔴 **Must-Have** — Absence will likely cause rejection
- 🟡 **Nice-to-Have** — Strengthens the paper meaningfully
- 🟢 **Low Impact** — Won't materially change the outcome

---

### 🔴 MUST-HAVE #1: Add Statistical Significance Tests
**Effort:** 2–3 hours (no GPU, analysis only)

Every comparison in the paper currently says "DenseNet ρ=0.434 vs ViT ρ=0.200" without testing if this difference is significant. With 5 folds, run:
- **Paired Wilcoxon signed-rank test** (non-parametric, appropriate for n=5) for every pairwise architecture comparison on agreement
- **Friedman test** (non-parametric repeated measures) across all 7 architectures
- Report p-values with a table in the paper

This is not optional. A BMVC reviewer *will* ask "are these differences significant?" and if you can't answer, it's an immediate weakness. This is the single highest-ROI action item.

**Impact on acceptance: +10–15%**

---

### 🔴 MUST-HAVE #2: Add One More Transformer Architecture
**Effort:** ~15–20 hours GPU (train + XAI benchmark on both datasets)

Add **DeiT-Small** or **Swin-Tiny** to both RSNA and CUB-200. This is the most expensive recommendation but also the most impactful.

Why this matters: Right now, your entire "Transformers disagree more" claim rests on ViT-Small. One model. A reviewer can dismiss this as "maybe ViT-Small's specific patch tokenization causes this, not Transformers in general." If DeiT-Small shows the same low agreement, the claim transforms from "ViT-Small is an outlier" to "Transformer architectures produce less consistent explanations." This is the difference between a borderline and a solid accept.

**Recommendation:** Use DeiT-Small (`deit_small_patch16_224` from timm) — it's the most directly comparable to ViT-Small and requires no architecture-specific handling.

**Impact on acceptance: +15–20%**

---

### 🔴 MUST-HAVE #3: Formally Exclude ConvNeXt from CUB-200 or Fix It
**Effort:** 0 hours (exclude) or ~5 hours GPU (retrain)

You have two options:

**Option A (Recommended — Exclude):** Remove ConvNeXt from all CUB-200 analysis. Add a transparent paragraph in the paper: *"ConvNeXt-Tiny failed to converge on CUB-200 under our training protocol (32% accuracy, see Appendix X for training curves). Since XAI evaluation requires competent classifiers, we report CUB-200 results for the four models achieving >70% accuracy. The RSNA ConvNeXt results (74.2% balanced accuracy) remain valid and are included in all RSNA analyses."* Include the failed training curve in supplementary to show you tried.

**Option B (Retrain):** Retrain ConvNeXt on CUB-200 with lower learning rate (1e-5 backbone), more epochs (50), and cosine annealing. If it converges, great. If not, go to Option A.

Do NOT leave ConvNeXt in the CUB-200 table with 32% accuracy and an asterisk. That invites a reviewer to question your entire experimental protocol.

**Impact on acceptance: +5% (removes a rejection vector)**

---

### 🟡 NICE-TO-HAVE #1: Perturbation Baseline Analysis for Insertion/Deletion
**Effort:** 3–4 hours (no GPU, reanalysis)

Run Insertion/Deletion with a different baseline (e.g., Gaussian noise, mean pixel, or random shuffle instead of black/zero). Report whether the faithfulness ranking changes with baseline choice. If it's stable, this strengthens the consensus map's credibility. If it changes, you have an important caveat to discuss.

This addresses Weakness W7 directly and preempts a reviewer concern about metric reliability.

**Impact on acceptance: +3–5%**

---

### 🟡 NICE-TO-HAVE #2: Saliency Stability Analysis
**Effort:** 5–8 hours GPU

For stochastic methods (GradientSHAP, Integrated Gradients with noisy baseline), run each method 5 times per image on a subset (e.g., 50 images, fold 0). Report the intra-method variance (how much does the same method's explanation vary across runs?) alongside the inter-method disagreement. If intra-method variance is low but inter-method disagreement is high, this strengthens the paper's core claim — the disagreement is between methods, not within them.

**Impact on acceptance: +3–5%**

---

### 🟡 NICE-TO-HAVE #3: Fix ViT-Small Fold 0 Attention Rollout
**Effort:** 30 minutes GPU

Re-run `run_xai_benchmark_v2.py` for `vit_small` fold 0 with the `**kwargs` fix. This gives you complete 5-fold data for Attention Rollout instead of 3-fold. Small but removes a gap.

**Impact on acceptance: +1–2%**

---

### 🟡 NICE-TO-HAVE #4: CNN-Only Sub-Analysis for Feature Coherence
**Effort:** 1–2 hours (analysis only)

The Feature Coherence section currently has n=5 (all architectures). Split it into:
1. **CNN-only analysis** (DenseNet, ResNet, ConvNeXt, EfficientNet = n=4): Report the within-CNN correlation more formally. Even with n=4, if the ordering perfectly matches (DenseNet > ResNet > ConvNeXt > EfficientNet for both coherence and agreement), a Kendall's tau or Spearman on 4 points is suggestive.
2. **Transformer as outlier analysis**: Frame ViT as a qualitatively different mechanism, supported by the gradient-pathway argument.

This doesn't fix the underpowered statistics but frames the finding more carefully.

**Impact on acceptance: +2–3%**

---

### 🟢 LOW IMPACT #1: Add LIME or KernelSHAP
**Effort:** 20+ hours GPU (very slow methods)
**Impact: +0–1%**

Not worth it. Occlusion covers the perturbation family. Cite Hedström et al. (2023) and move on.

### 🟢 LOW IMPACT #2: Learned Concepts for CBM (BiomedCLIP)
**Effort:** 15–20 hours + potential failure
**Impact: +2% if it works, −5% if noisy**

You already tried BiomedCLIP and it was noisy. Don't revisit. The metadata-derived concepts are defensible if framed correctly (see writing advice below).

### 🟢 LOW IMPACT #3: Third Dataset
**Effort:** 30+ hours GPU
**Impact: +3–5%**

Two datasets is sufficient for the cross-domain claim. A third dataset has diminishing returns relative to the effort. Only do this if you're targeting a Q1 journal.

---

## 6. GUARANTEED ACCEPTANCE BOOSTERS

These are things that, if done, are **guaranteed** to improve acceptance chances regardless of experimental results:

### G1. Release Code + Models Upon Acceptance
State in the paper: *"Code, trained models, and evaluation pipelines will be released upon acceptance."* Then actually do it. BMVC reviewers increasingly value reproducibility. This is a +3–5% boost for zero experimental effort.

### G2. Write a Compelling Abstract in the First 30 Words
The abstract must lead with the cross-domain finding, not the clinical motivation. For BMVC:

> *"Post-hoc explainability methods disagree — but is this a flaw of the methods, the data, or the model? We benchmark 7 XAI methods across 7 architectures on two fundamentally different domains (clinical spine MRI and CUB-200 birds) and show that disagreement is an intrinsic property of neural architectures: classic CNNs consistently agree (DenseNet ρ=0.43), while Transformers consistently disagree (ViT ρ=0.20). This hierarchy is invariant to imaging domain."*

The reviewer reads 30 words and already knows the punchline. This matters enormously.

### G3. A "Disagreement Gallery" Figure on Page 2
Put a figure on page 2 (ideally the first figure in the paper) showing one image from RSNA and one from CUB-200, each with 7 XAI heatmaps side by side. The visual impact of seeing GradCAM highlight the spinal canal while Integrated Gradients highlights the disc space — and the same incoherence on a bird image — is worth 1000 words. This should be your Figure 1.

### G4. A "Rank Stability" Table
A table showing the agreement ranking across all 5 folds for both datasets. If DenseNet is #1 in all 10 conditions (5 RSNA folds + 5 CUB folds), and ViT is last/near-last in all 10, that's a striking visual. Format it as:

| Fold | 1st | 2nd | 3rd | ... | 7th |
|------|-----|-----|-----|-----|-----|
| RSNA-0 | DenseNet | ResNet | CBM-NL | ... | ViT |
| RSNA-1 | DenseNet | ResNet | CBM-NL | ... | ViT |
| ... | | | | | |
| CUB-0 | DenseNet | ResNet | EffNet | ... | ViT |
| ... | | | | | |

If the columns are nearly monochromatic (same model name top to bottom), the visual argument is unassailable.

### G5. Soften the Title
"Architecture Governs Explanation" is strong but vulnerable. If EfficientNet flips ranks between domains and ConvNeXt fails on CUB-200, a reviewer can attack "governs." Consider:

> *"Architecture Shapes Explanation: A Cross-Domain Benchmark of Post-Hoc XAI Disagreement"*

"Shapes" is defensible even with mid-tier instability. "Governs" implies determinism that your data only partially supports.

---

## 7. SHOULD YOU START WRITING THE DRAFT?

**Yes — but in parallel with Must-Have #1 and #3.**

Here is my recommended timeline:

### Week 1 (Days 1–3)
1. **Run significance tests** (Must-Have #1) — 3 hours
2. **Make ConvNeXt exclusion decision** (Must-Have #3) — 1 hour
3. **Fix ViT fold 0 Attention Rollout** (Nice-to-Have #3) — 30 min
4. **Start writing the draft** — Section 1 (Introduction), Section 2 (Related Work), Section 3 (Methods)

### Week 1 (Days 4–5)
5. **Begin DeiT-Small training** (Must-Have #2) — kick off on Kaggle
6. **Continue writing** — Section 4 (Experimental Setup), Section 5 (Results — RSNA parts)

### Week 2 (Days 6–8)
7. **DeiT-Small training completes → run XAI benchmark** (Must-Have #2)
8. **Continue writing** — Section 5 (Results — CUB parts), Section 6 (Discussion)
9. **Create Figure 1: Disagreement Gallery** (G3)
10. **Create Rank Stability Table** (G4)

### Week 2 (Days 9–10)
11. **DeiT results arrive → integrate into paper**
12. **Run CNN-only coherence sub-analysis** (Nice-to-Have #4)
13. **Complete draft: Section 7 (Limitations), Abstract, Conclusion**
14. **First full read-through and revision**

### Week 3
15. **Polish, get feedback, revise**
16. **Prepare supplementary materials**

---

## 8. FINAL ASSESSMENT SUMMARY

| Question | Answer |
|----------|--------|
| **Is it worthy of a top-tier venue as-is?** | Borderline. ~45% at BMVC, ~75% at MIDL. Not ready for Q1 journal. |
| **Do you need more code running?** | **Yes.** Three must-haves: significance tests (2 hrs), one more Transformer (15–20 hrs GPU), ConvNeXt decision (0 hrs). |
| **What is the single highest-ROI action?** | Adding DeiT-Small. It transforms the core claim from "one Transformer behaves this way" to "Transformer architectures behave this way." |
| **What is the fastest win?** | Significance tests. Three hours of analysis, no GPU, immediate credibility boost. |
| **Should you start writing?** | Yes, immediately. Write in parallel with experiments. The writing process will reveal analytical gaps. |
| **What is guaranteed to increase acceptance?** | (1) Significance tests, (2) Second Transformer, (3) Disagreement gallery as Figure 1, (4) Code release commitment, (5) Softened title. |
| **Target venue recommendation?** | **Primary: MIDL 2027** (strongest fit, highest acceptance probability). **Secondary: BMVC 2027** (achievable with DeiT addition + strong writing). **Journal: defer** unless both conferences reject. |

---

## 9. PARTING NOTE

This project has gone through three rigorous iterations in five days, each addressing real flaws. That discipline is visible in the final product. The cross-domain finding is genuinely interesting — I have not seen another paper show that XAI disagreement hierarchy is an architecture property that survives domain transfer. That is your gem. Protect it by (a) giving it more Transformer evidence, (b) surrounding it with proper statistics, and (c) presenting it with a visual punch on page 2. Do those three things and you have a strong paper.




**kimi**:
Here is a rigorous, reviewer-style assessment of SpineXNet V3. I have evaluated it as if I were sitting on the senior program committee of BMVC or a similar top-tier venue (MICCAI/MIDL tier), because that is the standard you asked for.

---

## 1. Executive Verdict

**Current Status:** **Borderline Reject → Weak Accept** (with major revision required before submission).

**Bottom line:** You have built a **surprisingly comprehensive empirical benchmark** with genuine cross-domain value. The core finding—that XAI disagreement hierarchies are architecture-dependent and generalize from spine MRI to CUB-200—is a legitimate, novel observation that could interest a BMVC audience. However, **the paper is not yet top-tier ready**. There are specific experimental gaps, one likely bug, and a methodological framing issue that a competent reviewer will flag as fatal if unaddressed.

**My recommendation:** Do **not** start the final draft yet. Execute the **Tier 1 Must-Haves** below (estimated 1–2 days of GPU/code work). Once those are in, begin drafting immediately while the narrative is fresh.

---

## 2. Strengths (What Reviewers Will Praise)

| Strength | Reviewer Impact |
|----------|-----------------|
| **Cross-domain reproduction** | This is your single strongest asset. Showing that DenseNet > ResNet >> ViT in XAI agreement on *both* clinical MRI and fine-grained birds elevates the work from a medical application to a fundamental CV finding. |
| **Scale & rigor** | 7 architectures × 7 methods × 5-fold CV × 2 datasets is an unusually thorough benchmark. Most XAI disagreement papers use 2–3 models and 1-fold. |
| **Real expert annotations** | Using actual RSNA neuroradiologist coordinates instead of proxy ROIs defends you against the most common clinical-XAI criticism. |
| **Faithfulness-Weighted Consensus** | While simple, it is a sensible, principled aggregation scheme that prior work has not explicitly tested. |
| **CBM intervention story** | The 59.2% fix rate with non-leaky concepts is a compelling clinical hook. It turns the paper from a "complaint about XAI" into a "here is an alternative." |
| **Sanity checks included** | The Adebayo randomization test shows you understand current XAI methodological standards. |
| **Reproducibility** | Your codebase, configs, and Kaggle notebooks are better documented than 90% of submissions. |

---

## 3. Weaknesses (What Reviewers Will Attack)

| Weakness | Severity | Why It Hurts |
|----------|:--------:|--------------|
| **EfficientNet IG/GradSHAP identical failure (0.490)** | 🔴 **Critical** | Two distinct gradient methods producing *identical* suspiciously low scores on one architecture screams **implementation bug** (likely input normalization/baseline mismatch for EfficientNet). This undermines your entire faithfulness evaluation for that model and artificially inflates disagreement. |
| **CBM concepts are programmatic, not learned** | 🔴 **Critical** | Your "concepts" (`is_stenosis`, `laterality`, `level_position`) are deterministic functions of the metadata/labels. This is not a Concept Bottleneck Model in the standard (Koh et al.) sense; it is a **metadata-augmented classifier**. Reviewers will argue the CBM is not learning interpretable visual concepts but simply receiving the query type as input. |
| **No statistical significance testing** | 🟡 **Major** | You report mean ± std, but never test whether DenseNet’s agreement is *significantly* better than ViT’s, or whether the consensus map significantly beats the best individual method. At top tiers, "5-fold CV" is necessary but not sufficient—you need paired Wilcoxon/t-tests across folds. |
| **Missing simple baseline for consensus** | 🟡 **Major** | You propose faithfulness-weighted consensus, but do not compare it to a **uniform average** of all methods. If uniform averaging performs similarly, your method contribution collapses to an obvious baseline. |
| **Only one Transformer tested** | 🟡 **Major** | Claiming "Transformers disagree" based solely on ViT-Small is weak. Swin, DeiT, or CaiT would strengthen the claim. Compute constraints are understandable, but the limitation is glaring. |
| **Expert IoU is very low (max 0.26)** | 🟡 **Major** | You frame clinical alignment positively, but an IoU of 0.26 means explanations overlap with expert regions only ~1/4 of the time. For a clinical audience, this is evidence that post-hoc XAI is *clinically useless*, not aligned. The narrative needs to pivot. |
| **ConvNeXt CUB-200 failure (32% acc)** | 🟡 **Major** | A 200-class fine-grained dataset is standard. ConvNeXt failing to converge suggests a hyperparameter issue. Excluding it without a strong justification looks like cherry-picking. |
| **Attention Rollout incomplete (RSNA fold 0)** | 🟢 **Minor** | Easy to fix, but sloppy if left missing. |
| **Weak theoretical contribution** | 🟡 **Major** | The Feature Coherence analysis yielded a negative result. That is publishable as an informative negative, but it leaves the paper without a mechanistic explanation for *why* architectures differ. Benchmark papers at top tiers increasingly need a "why," not just a "what." |

---

## 4. Reviewer Scorecard

Rated on a 1–5 scale (5 = excellent, 3 = borderline, 1 = poor).

| Parameter | Score | Reviewer Commentary |
|-----------|:-----:|---------------------|
| **Novelty & Contribution** | 3.0 | The cross-domain generalization finding is genuinely interesting, but the consensus method is incremental and the disagreement problem itself is well-trodden (Krishna et al.). Needs stronger differentiation from prior benchmark studies. |
| **Technical Rigor** | 3.0 | Large-scale and well-organized, but the EfficientNet gradient bug, lack of significance testing, and programmatic CBM concepts are serious flaws. |
| **Experimental Breadth** | 4.5 | Excellent coverage of architectures and methods. Would be a 5 with one more Transformer and a fixed ConvNeXt. |
| **Statistical Rigor** | 2.5 | 5-fold CV is good. Bootstrap CIs are good. But **no hypothesis testing** across folds/methods is a glaring omission for a benchmark paper. |
| **Clinical Relevance (MIDL)** | 3.0 | Low expert IoU and programmatic concepts weaken the clinical story. The intervention demo is nice but limited. |
| **CV Impact (BMVC)** | 4.0 | The architecture-dependent, cross-domain disagreement pattern is exactly the kind of empirical finding BMVC accepts if framed as a fundamental phenomenon. |
| **Reproducibility** | 5.0 | Exceptional. Code, configs, notebooks, and documentation are publication-ready. |
| **Overall (Top-Tier Ready?)** | **3.0** | **Borderline.** With Tier 1 fixes, this rises to 3.5–4.0 (competitive). As-is, it risks a reject at BMVC/MIDL and a major revision at a Q1 journal. |

---

## 5. Priority Action Plan

### 🔴 Tier 1: Must-Have (Do These Before Writing)
*Without these, the paper has a >70% chance of rejection at top tiers.*

| # | Action | Rationale | Effort |
|---|--------|-----------|:------:|
| 1 | **Debug EfficientNet IG/GradSHAP** | Identical scores of 0.490 for two different gradient methods is almost certainly a normalization/baseline bug. Check that your IG baseline (black/gray image) matches EfficientNet’s `normalize` mean/std. If it is real, you need a compelling explanation (e.g., "EfficientNet’s compound scaling shatters gradients"). | 2–4 hrs |
| 2 | **Add Uniform Consensus Baseline** | Compute a simple unweighted average of all 7 attribution maps. Compare its Insertion AUC to your faithfulness-weighted version. If the gap is small, reframe your contribution as "a large-scale validation of consensus aggregation" rather than a novel method. If the gap is large, you have a strong result. | 2 hrs |
| 3 | **Statistical Significance Tests** | Run paired Wilcoxon signed-rank tests (or paired t-tests) across your 5 folds for: (a) DenseNet vs. ViT agreement, (b) Consensus vs. Best Individual method, (c) RSNA vs. CUB architecture ranking correlation. Report p-values in tables. | 3 hrs |
| 4 | **Clarify/Defend CBM Concepts** | Add a paragraph explicitly stating: *"We use deterministic clinical concepts derived from metadata to ensure perfect concept fidelity, isolating the effect of architecture on explanation disagreement from concept prediction noise."* If possible, add a sentence acknowledging that learned visual concepts are future work. | Editorial |
| 5 | **Fix or Justify ConvNeXt CUB** | Either (a) retrain ConvNeXt on CUB-200 with a lower learning rate (`1e-5` backbone) and longer warmup, or (b) exclude it transparently: *"ConvNeXt-Tiny failed to converge under our standard protocol (32% accuracy); we report CUB-200 results for the four converged models."* Option (b) is safer and acceptable if honest. | 0 hrs (exclude) or 4 hrs (retrain) |
| 6 | **Complete ViT Fold 0 Attention Rollout** | Re-run with your `**kwargs` fix. | 30 min |

### 🟡 Tier 2: High-Impact (Strongly Recommended)
*These will meaningfully move the needle with skeptical reviewers.*

| # | Action | Rationale | Effort |
|---|--------|-----------|:------:|
| 7 | **Reframe Clinical Alignment Narrative** | Do not claim "clinical alignment." Instead, report: *"Expert IoU reveals poor anatomical alignment across all post-hoc methods (max 0.26), confirming that current XAI fails to highlight clinically relevant regions despite high faithfulness scores."* This turns a weakness into a powerful negative result. | Editorial |
| 8 | **Add Disagreement Qualitative Figure** | A 7-panel figure showing the same MRI slice with GradCAM, IG, Occlusion, etc., side-by-side is **mandatory** for any XAI paper. Humans are visual; reviewers need to *see* the disagreement. Include one spine and one bird example. | 3 hrs |
| 9 | **Ablation: Consensus with N Methods** | Test consensus using only the top-3 most faithful methods vs. all 7. Does adding low-faithfulness methods hurt? This adds methodological depth. | 3 hrs |
| 10 | **Compare to Prior Aggregation Work** | Search for "ensemble XAI," "explanation fusion," or "consensus saliency." Cite and compare quantitatively. If none exist, explicitly claim: *"To our knowledge, this is the first work to use empirical faithfulness to weight XAI consensus."* | 4 hrs (lit review) |
| 11 | **Add One More Transformer (if compute allows)** | Swin-Tiny or DeiT-Small. Even training just 2 folds on RSNA would let you say "the pattern holds across two Transformer families." This dramatically strengthens generalizability. | 8–12 hrs GPU |

### 🟢 Tier 3: Nice-to-Have (Polish)
*These improve perceived thoroughness but are unlikely to change the accept/reject decision.*

| # | Action | Rationale |
|---|--------|-----------|
| 12 | **Feature Coherence: CNN-only analysis** | Report the near-perfect correlation (r≈0.99) within the CNN family separately. Frame the overall null result as: *"Feature coherence predicts agreement for CNNs, but ViT violates this relationship, revealing a categorically different mechanism."* |
| 13 | **Correlation: Faithfulness vs. Agreement** | Do architectures with higher faithfulness also have higher inter-method agreement? A scatter plot of Mean Faithfulness vs. Mean Spearman ρ would be insightful. |
| 14 | **Attention Rollout as "architecture-native" analysis** | Expand the finding that Attention Rollout beats GradCAM on ViT. This is a nice secondary contribution. |

### ⚪ Tier 4: Skip (Low ROI or Risky)
*Doing these now costs time without proportional benefit.*

| Item | Why Skip |
|------|----------|
| **BiomedCLIP features** | You said they were noisy and uncorrelated. Including weak results dilutes the paper. |
| **LIME / KernelSHAP** | Too slow, and Occlusion already covers the perturbation family. |
| **Human radiologist user study** | Extremely high effort. A proper study needs IRB, 5+ radiologists, and weeks of time. Without it, the paper is still viable as a benchmark. |
| **Re-run GLS** | You already replaced it with Feature Map Smoothness. GLS is deprecated. |

---

## 6. Strategic Venue & Narrative Advice

### Target Venue: **BMVC > MICCAI > MIDL**
- **BMVC:** Your cross-domain finding (CUB-200 + RSNA) is a fundamental CV result. Lead with CUB-200 in the abstract to signal this is not a niche medical paper. The clinical data becomes the "practical validation."
- **MICCAI:** Possible if you lean heavily into the CBM intervention and expert annotations, but the low Expert IoU and programmatic concepts make this riskier.
- **MIDL:** Harder. MIDL reviewers expect stronger clinical integration or theoretical ML novelty. Your clinical story is currently too thin for MIDL's standard.
- **Q1 Journal (e.g., Pattern Recognition, MedIA):** If you prefer a journal, add the Tier 2 items and submit to **Pattern Recognition** or **Computer Vision and Image Understanding**. Journals allow longer exposition, which suits benchmark papers.

### Narrative Pivot (Critical)
Your current narrative tries to be both a clinical paper and a CV paper. **Pick one.** I recommend the **BMVC narrative**:

> *"We reveal that post-hoc XAI disagreement is an intrinsic property of neural network architectures, not a domain-specific artifact. Through a large-scale benchmark on clinical MRI and fine-grained bird classification, we show that classic CNNs (DenseNet, ResNet) produce significantly more consistent explanations than modern architectures (ViT, EfficientNet). To resolve this, we propose a faithfulness-weighted consensus that matches or exceeds any individual method."*

- **De-emphasize:** "Clinical alignment" (your IoU is too low).
- **Emphasize:** Cross-domain stability, architecture hierarchy, and consensus as a practical tool.

### Title Recommendation
Keep your working title, but make the architecture hierarchy explicit:
> **"Architecture Governs Explanation: A Cross-Domain Benchmark of Post-Hoc XAI Disagreement"**

Avoid cute titles like "From Spines to Birds" for a top-tier submission; they signal a lack of seriousness to some reviewers.

---

## 7. Final Recommendation: Draft or Experiment?

**Do not start the final manuscript yet.** Execute **Tier 1 (Must-Haves)** first. Here is the timeline I recommend:

| Day | Task |
|-----|------|
| **Day 1 (Today)** | Fix EfficientNet IG/GradSHAP bug. Run uniform consensus baseline. Complete ViT Fold 0 Attention Rollout. |
| **Day 2** | Run all statistical significance tests. Add ablation for consensus with top-3 methods. Generate qualitative disagreement gallery. |
| **Day 3** | Begin drafting **simultaneously** with code fixes. Start with the BMVC narrative: Abstract, Introduction, and Methods. |
| **Day 4–5** | Draft Results and Discussion. Insert figures. |
| **Day 6** | Internal review: Check that every claim is backed by a p-value or confidence interval. |
| **Day 7** | Mentor/colleague review if possible. |

**If you complete Tier 1 and Tier 2 items, this paper becomes a solid, competitive submission for BMVC or a strong Q1 journal.** It will not be a guaranteed accept—benchmark papers are inherently competitive—but it will earn a fair review and has a genuine chance.

If you submit **as-is**, the EfficientNet bug and lack of significance testing will likely trigger a confident reject from at least one reviewer, and that is often enough to sink a borderline paper.

You have done the hard work. The remaining fixes are surgical. Finish them, then write the draft with confidence.